Biotech rarely moves in straight lines, but every so often a pivotal readout can reshape a company’s trajectory overnight. That’s what happened this week for Capricor Therapeutics Inc. (NASDAQ:CAPR), which unveiled late-stage data for its Duchenne muscular dystrophy (DMD) cell therapy that sent its shares up as much as 500% in Wednesday trading — followed the next day by a public equity offering as the company moved quickly to build on that momentum.
The reaction was striking even by small-cap biotech standards. Shares of the US-listed company are still up more than 380% since Tuesday, despite a pullback on Thursday. It's a sharp reversal from July, when the stock tumbled after the US Food and Drug Administration rejected Capricor’s initial approval bid for Deramiocel.
Read more: Capricor Therapeutics shares tumble as FDA rejects Duchenne muscular dystrophy drug application
The surge underscores how pivotal data can rapidly shift expectations in rare-disease drug development, bringing the conversation from clinical benefit to regulatory strategy and the infrastructure required to support it.
A decisive Phase 3 readout
The driver of this week’s excitement was Capricor’s topline release from its pivotal Phase 3 HOPE-3 study of Deramiocel, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy.
The 106-patient, randomised, placebo-controlled trial met both its primary endpoint — Performance of the Upper Limb (PUL v2.0) — and its key cardiac secondary endpoint, left-ventricular ejection fraction (LVEF), achieving statistical significance on each (p=0.03 and p=0.04, respectively). According to the company, Deramiocel slowed skeletal muscle disease progression by 54%, while delivering a 91% slowing of decline in LVEF, a metric tightly linked to long-term survival in Duchenne.
CEO Linda Marbán called the results “strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy, demonstrating statistically significant improvements in both skeletal and cardiac function”. She added that the data reinforce the durability previously observed in the HOPE-2 program and should address the clinical issues raised in the FDA's Complete Response Letter denying the initial application.
Clinicians involved in the study underscored the significance of the findings. National principal investigator Craig McDonald, of UC Davis Health, said a nearly 54% slowing of upper-limb deterioration is “extraordinary in Duchenne and directly linked to maintaining independence and quality of life in the most severely affected patients with greatest unmet need”.
Vanderbilt University Medical Center cardiologist Jonathan Soslow added that stabilising cardiac function represents a meaningful advance for patients living with Duchenne cardiomyopathy — the leading cause of mortality in the disease.
Safety remained consistent with prior experience, and baseline characteristics were well balanced, with most participants already on cardiac medications and more than three-quarters having established cardiomyopathy at enrolment.
The natural next step: Raising capital
Against those clinical results, Capricor’s move on Thursday to launch an underwritten public offering was unsurprising. The company plans to issue common stock with a 15% overallotment option, with proceeds directed toward development and manufacturing of its product candidates, including Deramiocel, as well as general corporate purposes. Piper Sandler and Oppenheimer are serving as joint bookrunners.
Capricor has not yet disclosed the size of the offering, and completion remains subject to market conditions. Still, the timing is clear enough: after a sharp, data-driven rerating, raising capital while momentum is high is a well-established pattern in late-stage biotech — particularly for programs preparing for regulatory engagement and the manufacturing demands that come with it.
A broader signal for the sector
For the cell and gene therapy ecosystem, the HOPE-3 data land at a notable moment. Investor sentiment has been gradually improving, but clear evidence of functional benefit in a severely affected Duchenne population offers something rarer: a late-stage dataset that appears both robust and clinically meaningful.
Capricor’s existing commercial partnership with Nippon Shinyaku for potential US and Japan distribution adds another layer — reinforcing that even as regulatory work continues, the scaffolding for real-world delivery is already under construction.
What comes next?
Capricor now plans to submit its formal response to the FDA’s Complete Response Letter, incorporating the HOPE-3 data in line with earlier agency guidance that the study should be sufficient to support approval.
How the share price settles after this week’s volatility is an open question. But for a space where meaningful gains have been hard-won, the HOPE-3 data add a new point of reference — one that will be followed closely as the next phase of review unfolds.